Table 1.
Clinical trials investigating therapeutic approaches targeting inflammation and immunomodulatory effects in KRAS-induced cancers.
| Target(s) | Trial number | Phase | Drug(s) | Combination drug(s) | Cancer type | Current status |
|---|---|---|---|---|---|---|
| IL-6 | NCT00841191 | I/II | Siltuximab (CNTO 328) | — | Solid tumours | Completed |
| PD-1 | NCT03777124 | II | SHR-1210 | Apatinib | NSCLC | Not yet recruiting |
| PD-1 or PD-L1 | NCT04185883 | I | PD-L1 or PD-1 inhibitors | Sotorasib (AMG 510) | Solid tumours | Recruiting |
| PD-1 | NCT03785249 | I/II | Pembrolizumab | MRTX849 | Solid tumours | Recruiting |
| PD-1 | NCT03299088 | I | Pembrolizumab | Trametinib | NSCLC | Recruiting |
| PD-1 | NCT03225664 | I/II | Pembrolizumab | Trametinib | NSCLC | Recruiting |
| PD-1 | NCT03991819 | I | Pembrolizumab | Binimetinib | NSCLC | Active, not recruiting |
| PD-1 | NCT03948763 | I | Pembrolizumab | mRNA-5671/V941 | NSCLC, CRC, PDAC | Recruiting |
| PD-1 | NCT03004105 | II | Durvalumab (MEDI4736) | Selumetinib | NSCLC | Withdrawn (insufficient funding) |
| PD-L1 | NCT03637491 | I/II | Avelumab | Binimetinib | Metastatic PDAC and KRAS-mutant solid tumours | Recruiting |
| JAK1/2 | NCT02258607 | I | Momelotinib | Trametinib | Metastatic NSCLC | Terminated |
CRC colorectal cancer, IL-6 interleukin-6, JAK1/2 janus activated kinase 1/2, NSCLC non-small-cell lung cancer, PD-1 programmed cell death protein 1, PDAC pancreatic ductal adenocarcinoma, PD-L1 programmed death-ligand-1.